Opexa shares in meltdown

On Friday Opexa Therapeutics announced that its lead therapy--the MS drug Tovaxin--failed a Phase IIb trial with 150 patients. Researchers said that the therapy demonstrated a positive trend in reducing the annual relapse rate of patients, but said that a higher number of brain lesions in the Tovaxin group skewed the data. Investors, though, fled the stock. Opexa shares lost 92 percent of their value in the afternoon. Opexa release